Stoke and Biogen to present zorevunersen data at epilepsy conference

Stoke Therapeutics Inc. (NASDAQ: STOK) and Biogen Inc. (NASDAQ: BIIB) announced they will present data on zorevunersen at the 2025 American Epilepsy Society Annual Meeting from December 5-9 in Atlanta.

The presentations will include four years of clinical data from Phase 1/2a and ongoing open-label extension studies of zorevunersen, an investigational antisense oligonucleotide being evaluated for treating Dravet syndrome. The companies will present new propensity weighted analyses and electroencephalogram assessment findings.

Dravet syndrome is a severe developmental and epileptic encephalopathy characterized by recurrent seizures and significant cognitive and behavioral impairments. Most cases are caused by mutations in the SCN1A gene, leading to insufficient levels of NaV1.1 protein in brain neuronal cells.

Zorevunersen is designed to increase functional NaV1.1 protein production from the non-mutated copy of the SCN1A gene. The drug has received orphan drug designation from the FDA and EMA, along with breakthrough therapy designation and rare pediatric disease designation from the FDA.

The companies will present four studies at the conference, including one oral presentation and three poster presentations covering long-term extension studies, quality of life improvements, and electrophysiological improvements in patients treated with zorevunersen.

Zorevunersen is currently being evaluated in the global Phase 3 EMPEROR study in children and adolescents with Dravet syndrome. Under their collaboration agreement, Stoke retains exclusive rights in the United States, Canada, and Mexico, while Biogen has exclusive commercialization rights for the rest of the world.

The information is based on a press release from the companies.

You May Also Be Interested In